RK

Ratnesh Kumar

Active Director Director DIN 08440238
DIN 08440238 First appointment May 2019 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2019
Shareholding value •••• Premium profile

About Ratnesh Kumar

Data last updated:

Ratnesh Kumar is a Director at Scafell Pharmaceuticals Private Limited (since 2019). The company operates in Healthcare. Scafell Pharmaceuticals Private Limited reported revenue of ₹55,745 (FY 2022).

DIN 08440238
Primary Designation Director
Industry Healthcare
First Appointment 01 May 2019
Oldest Company Age 7 yrs
Largest company Scafell Pharmaceuticals Private Limited · ₹55,745 (FY 2022)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 May 20192019₹55,745 (FY 2022)Active

Board colleagues of Ratnesh Kumar

Directorship timeline

Open interactive timeline →
Scafell Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ratnesh Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ratnesh Kumar

Ratnesh Kumar currently holds 1 directorship: Scafell Pharmaceuticals Private Limited (Director, since 01 May 2019, revenue ₹55,745 (FY 2022)).

Ratnesh Kumar was first appointed on 01 May 2019 as Director at Scafell Pharmaceuticals Private Limited.

The current boards of Ratnesh Kumar's companies include Rajesh Kumar Singh (Scafell Pharmaceuticals Private Limited), Subodh Kumar Sinha (Scafell Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available